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Evaluation of Cellular-level Haversian Bone Resorption 
in Human Hyperparathyroid States 
A Pre l im inary Report 
H . M. Frost, M.D.,* A. R. Villanueva, B.S.,** Z. F. Jaworski, M.D.,*** 
P. Meunier, M.D.t and A. G. Shimizu, M.D.tt 
Cellular-level bone resorption was evaluated in 16 patients undergoing renal 
dialysis and in two with primary hyperparathyroidism, by quantitative histo-
logical means using tissue time markers. When averaged over periods greater 
than two weeks, the individual osteoclasts in these patients resorbed less bone 
in unit time than normal. 
This article reports an evaluation 
of an index of the speed of cellular-
level haversian bone resorption in 
human subjects with naturaUy occur-
ring hyperparathyroid states. Such an 
evaluation has relevance for at least 
four reasons. 
First, direct measurements of this 
activity in bone have never been re-
ported before, either in human or in 
experimental material;i indeed, some 
believe it impossible to measure this 
activity in human material. 
Second, many assume that parathy-
roid hormone makes osteoclasts in-
dividually "voracious."'-^ 
Third, humans with naturally oc-
curring metabolic bone disease provide 
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the actual bone dynamic abnormali-
ties which experimental work must 
subsequently explain in detail. Such 
patients have usually been iU long 
enough by the time of diagnosis and 
bone biopsy to provide a reasonably 
reliable steady state with respect to 
any abnormal bone dynamics that 
characterize their disease.* 
Fourth, when imbalance between re-
sorption and formation exists for many 
months, the bones act as living in-
tegrators of this imbalance, showing 
progressively enlarging and unambig-
uous morphological consequences. One 
can measure such changes accurately 
and directly in bone biopsies, and 
given the time factor one can express 
them as rates. 
Materials 
1) This study includes 16 patients 
with chronic renal failure who were 
on repeated renal dialysis, and from 
whom l l t h rib biopsies were sent to 
us by A. G. Shimizu, M.D.; R. G. 
Yaworski, M.D.; P. Kenmore, M.D.; 
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and J. Pierce, M.D. These 4 women 
and 12 men had clinical symptoms of 
uremia for an average of 1.47 years, 
and they averaged 36.1 years of age. 
High levels of circulating parathyroid 
hormone (PTH) have been found in 
such patients by others.* All 16 of these 
patients had clear evidence of renal os-
teodystrophy, revealed by histological 
examination of their l l t h rib biopsies,-* 
and most of them had had serum 
chemical evidence of azotemia, and 
presumably, therefore, had abnormal 
bone dynamics for much longer than 
their clinical uremic symptoms. 
2) Two women in this study had 
proven primary hyperparathyroidism, 
and yielded l l t h rib biopsies at the 
time of removal of their parathyroid 
adenoma. 
Table I briefly summarizes the case 
material. 
Methods 
1) Labels, Biopsies and Sections: 
All patients were given one or more 
oral tetracycline bone markers of dem-
ethylchlortetracycline in vivo. Biopsy 
of the anterior third of the l l t h rib 
was subsequendy performed and the 
specimen was forwarded to the lab-
oratory in 70% ethanol. At least 
six undecalcified, accurately oriented 
cross-sections .07mm thick were made 
upon receipt of the biopsy and stained 
with the Villanueva osteochrome bone 
stain, except for one section per case 
which was not stained. This was to 
ensure by comparison under the fluor-
escence microscope that the staining 
procedures had not eluted and/or ob-
scured the tetracycline labels.'^ ' " 
2) Rationale: The mathematical, 
histological and physiological relations 
TABLE I 
Clinical Data on 14 Renal Dialysis Patients 
Case 
Number 
Patient's 
Initials Diagnosis Age Sex 
Duration of 
Symptoms 
before Rib 
Biopsy (mos.) 
BUN Serum 
Creatinine 
Img/lOOmI) (mg/lOOmI) 
Serum 
Calcium 
(mg/lOOmI) 
Serum 
Phosphorus (mg/lOOmI) 
Alkaline 
Phosphatase 
(K.A.U.I 
1 CG. Uremia 30 F 5 146 17.6 10.1 8.96 4.8 
2 P.S. 
" 
30 F 40 225 21.6 8.0 15.6 8.4 
3 G.S. 47 M 36 n.a. n.a. 8.5 8.3 n.a. 
4 W.B. 36 M 5 164 24.4 5.0 11.5 12.0 
5 LV. 38 F 7 186 28.4 7,4 7.2 10.8 
6 W.H. 46 M 25.5 158 22.4 7.8 9.9 10.8 
7 E.T. 
" 
37 F 13 160 16.8 7.5 7.6 7.2 
8 R.S. 29 M 11 182 23.0 9.5 14.2 4.8 
9 E.Y. 36 M 26 129 24.0 7.5 8.8 9.6 
10 B.B. 30 3.5 164 18.0 9.3 8.5 14.6 
11 A.L. 
" 
4J M 7.5 215 28.0 8.5 13.7 12.0 
12 J.B. i? M 23 145 16.0 4.5 7.45 9.6 
13 F.S. 
" 
48 fvl 30 103 15.1 9.0 7.:^  16.8 
14 D.H. 30 M 18.5 134 19.4 .8.0 6.0 9.0 
15 P.H. 22 M 12 121 16.7 8.5 7.1 8.6 
16 P.M. 33 M 20 163 21.0 8.6 8. 8 10.4 
17 L.H. iOHPTH 42 F 24 21 .6 11.2 2.1 5.0 
18 E. R. i° HPTH 63 F 24 15 1.0 12.1 2.0 4.9 
The major clinical features of the case material in the present study are summarized. 
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which allow determination of cellular 
level resorption by quantitative histo-
logical means have been outlined else-
where.Based on the use of a mini-
mum of two tissue time markers for 
formation, and on two more for bone 
loss or gain, these relations are de-
scribed next. The basic relation is: 
When one sums all bone formation and 
resorption over previous time, their 
difference equals the amount of bone 
present. In a modified derivative form, 
the relation becomes: If the mean bone 
formation (dF) and resorption (dR) 
rates are added up during a disease, 
their difference equals the mean rate 
of loss or gain (dB) during the disease. 
In exactly equivalent symbols: 
dF + dR = dB (Equation 1) 
Given meaningful values for dF and 
dB, one then solves this equation for 
dR. Such values can be obtained by 
the following means: 
dF, the bone formation rate, can be 
measured accurately by two available 
means."' " Here, dB represents the 
rate of net loss of bone on the haver-
sian envelope during a disease, and 
any such loss must progressively in-
crease the intracortical porosity, an 
enlargement easily detected and meas-
ured by comparing measurements of 
this property in biopsies of diseased 
patients to comparable samples of 
normal persons. Here, the normals re-
veal the probable status of the patients 
before they become ill ("marker" #1 
for bone loss), while the patients re-
veal any cumulative imbalance that 
resulted during their disease ("marker" 
#2 for bone loss).!'' These differences, 
divided by the duration of the disease 
over which they developed, become 
the mean rate of loss, i.e., dB in 
equation (1) . Converse, arguments ap-
ply to net bone gain. Therefore dB 
is determinate, in histological practice 
as well as in theory. 
Given values for both dF and dB, 
solving equation (1) for dR yields: 
dR = dB — dF (Equation 2) 
Now dR represents the bone resorp-
tion rate, and in histological terms 
this also equals the product of that 
fraction of an envelope's surface under-
going resorption at any moment (R), 
times the mean depth of bone eroded 
from that fraction in unit time by os-
teoclasts (Mr). ' ' Therefore we can 
"resolve" dR as the product of the 
above two parameters, thus: 
dR = R Mr (Equation 3) 
(R), the fractional resorption sur-
face, can also be measured accurately 
and directly in bone sections. While 
Mr, the depth of bone eroded in unit 
time, cannot be so measured, we can 
now express it as a unique relation to 
other parameters which can be meas-
ured directly, by first substituting 
equation (3) into (2) : 
R Mr = dB — dF (Equation 4) 
and then dividing both sides by R: 
M r — dF (Equation 5) 
R 
3) Measurements: To obtain values 
for the right hand terms of equation 
(5), these measurements of haversian 
remodeling were made by methods 
outlined in the cited references. The 
bone formation rate (dF) in units of 
mm- bone formed/mm envelope pe-
rimeter/year,''' and the decimal 
fraction of the total haversian perhn-
eter covered by Howship's lacunae 
( R ) . " To find dB, the total haversian 
perimeters in the sections,and the 
intracortical porosities,were meas-
ured. 
Haversian ^dB: A patient's intra-
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cortical porosity was subtracted from 
his age-comparable norm to obtain the 
net change (if any) during his disease, 
subject only to the uncertainty due to 
normal variation in porosity. One S.D. 
variation in this porosity represents an 
amount of bone equal to an 8.2% 
change in the normal Mr over a period 
of 1.47 years, which represents a rela-
tively small uncertainty in the value of 
Mr in an individual case. Positive 
values of dB imply a deficit, negative 
values an excess, of resorption relative 
to formation. For each patient this 
value was then divided by the dura-
tion of his uremic symptoms, to ex-
press bone loss or gain as a mean 
annual rate. When divided by the 
total haversian perimeter, loss or gain 
appears as mm^ of compacta/milli-
meter of haversian envelope/year. 
At this point numerical values were 
substituted into each term on the right 
of equation (5), the necessary arith-
metic done, and Mr obtained, separ-
ately for each case. 
4) Normals: Since norms were ob-
tained by similar methods, any syste-
matic errors in the work should affect 
both patients and norms equally. Such 
errors in any event do not exceed one 
part in 20, which constitutes the known 
absolute accuracy of this work in our 
hands. 
Table I I summarizes the data along 
with the norms required for compari-
son. 
Results 
1) Haversian Radial Resorption 
Rate: At .106 .1 mm/year, the 
mean Mr of the dialysis group aver-
aged 29.5% of the norm for age 36.1 
years. The mean of the two women 
with primary hyperparathyroidism 
averaged 68% of their mean normal. 
The scatter plot in Figure 1 shows the 
distribution of Mr values after express-
ing the value in each patient as a per-
cent of his age-comparable norm. 
2) Evaluation of Reliability: Di-
alysis cases: Equation (5) shows that 
Mr decreases inversely proportionally 
to R, and directly proportionally to 
dF and dB. In the dialysis group (R) 
was supernormal in 15 patients (aver-
TA_B_Li; M 
Haversian Envelope 
Group Dialysis 
16(4) 
Comparable 
Normal 
143(12) 
Primary 
Hyperparathyroidism 
2(-) 
Comparable 
Normal 
81 (9) 
Parameter Units 
Fractional Formation Surface (F) mm/mm .04 + .1 .04 + .015 .16 .04 + .015 
Fractional Resorption Surface (R) mm/mm . 185 1 .01 .03 + .01 .12 .03 + .01 
Rate of bone loss (dB) 9 mm'/mm/yr -. 0083 -.0006 -.007 -.0006 
Radial Closure Rate (Mj) mm/yr .023 + .02 . 34 + .12 .064 .28 + .1 
Radial Resorption Rate (1V1|.) mm/yr . 106 i . 1 . 36 i .1 .15 .22 + .07 
For each patient group, the mean data required to compute the radial resorption rates are 
listed. These rates were computed separately from the raw data for each case, so tljc 
mean radial resorption rate for a given group will not agree exactly with that which is 
computed from the listed mean values of the raw data. 
262 
Cellular-level Haversian Bone Resorption in Human Hyperparathyroid States 
age 350% of normal), and slightly 
subnormal in one patient (90% of 
normal), so the group's increase in R is 
significant (p.<.001) and greatly ex-
ceeds the errors of measurement. dF 
was subnormal in 15 patients (average 
34% of normal), and normal in one, 
so that this depression too is significant 
(p.<.001), and it also greatly exceeds 
the errors of its measurement. dB was 
elevated in 14 and decreased in 2 pa-
tients (average net increase equaled 
—.009% ) and although small, it dif-
fers significantly from the normal value 
of —.0005 mmVmm/year (p.<.01), 
and exceeds by a factor of three the 
errors of its measurement. 
Primary hyperparathyroid cases: 
In these two women all of the haver-
sian parameters were between one and 
two S.D. different from normal in that 
direction which lowered the value of 
Mr, except the intracortical porosity, 
which was 3 S.D. larger than normal in 
each, tending to raise the Mr value. In 
spite of this, their mean Mr was low, 
their increased porosities reflecting 
relatively greater depressions of tissue-
level bone formation than of resorp-
tion. Although their abnormal changes 
were at least 10 times larger than the 
errors of measurement, there are too 
few of these patients, and then: ab-
normalities are too small, to achieve 
an acceptable level of statistical con-
fidence. 
In sum then, the depressed Mr in 
the dialysis group is significant, but 
due to a limited sample that seen in 
the primary hyperparathyroid women 
is not. Other factors reenforcing these 
conclusions will be given shortly. 
It is important to note here a dy-
namic peculiarity of the analytical sys-
tem that was employed: It averages Mr 
o 
00% 4oa 
o 
o 
o A 
o 
• A 
HAVERSIAN 
Figure 1 
Scatter plot of haversian radial resorption 
rates, normalized to sex, age- and bone-
comparable norms. Circles: dialysis cases. 
Triangles: primary hyperparathyroid cases. 
Squares: secondary hyperparathyroidism. 
The single greatly supernormal haversian 
value is considered to arise from a greatly 
underestimated duration of disease. Never-
theless the value of this case was included 
in computing the dialysis group's mean M.-
value. 
over time periods equal to or longer 
than the tetracycline labeling interval, 
which was approximately two weeks. 
Consequently these findings do not rule 
263 
Frost, Villanueva, Jaworski, Meunier and Shimizu 
out the possibility that Mr might tem-
porarily reach normal or even super-
normal values over much shorter per-
iods of time, although they do make 
it very unlikely that the average Mr 
over longer periods of time was normal 
or supernormal. 
Discussion 
A subnormal radial resorption rate 
alone does not reveal the relative ac-
tivity of the typical individual osteo-
clast, that is whether it is supernormal, 
normal or subnormal." However, 
other information permits these de-
ductions : 
First, the fractional resorption sur-
face (R in Table I I ) was greatly in-
creased in these cases, similar to find-
ings noted by others in similar ma-
terial.17-19 
Second, and somewhat unexpectedly, 
the tissue-level haversian bone resorp-
tion rates were subnormal in the 
dialysis group, as satisfaction of equa-
tion (2) with the data shown (p.<.01) 
and as was predicted by others.-" It 
was normal in the two women with 
primary hyperparathyroidism (Fig 2). 
Third, multiple observers consis-
tendy found osteoclasts in greatly in-
creased numbers in these states." '^ --
When more osteoclasts lie on an en-
larged resorption surface, yet resorb 
less bone, in terms both of quantity 
resorbed and of depth eroded in unit 
time, then individual osteoclasts resorb 
bone at subnormal average speed. The 
real question then is not whether this 
is so but rather: how much so? 
Two further points enhance the reli-
ability of the above conclusion: 
One, these cases had serum chemical 
200%-^ 
100%--^A-^ 
0-
Haversion 
Resorption Rote 
Figure 2 
Tissue-level haversian bone resorption rates 
of each case, normalized to age- and bone-
comparable norms. Circles: dialysis cases. 
Triangles: primary hyperparathyroidism. 
The three greatly supernormal values are 
probably spurious, and attributable to un-
derestimating durations of bone disease 
which, based on clinical symptoms of ur-
emia, were .29, .42 and .47 years. By serum 
chemical tests all three cases had had 
azotemia for more than two years, and 
recomputation on that basis would have 
brought each of these rates below normal. 
evidence of azotemia longer than they 
had clinical symptoms of uremia, so 
the estimates of the durations of their 
bone diseases are probably conserva-
tive; this caused the computed Mr 
values to be higher than the true ones. 
Two, some of the increased porosity 
which was involved in computing dB, 
and which tends to raise the computed 
values of Mr, represents a purely tem-
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porary and nonprogressive bone loss 
which always accompanies increased 
numbers of bone resorbing and form-
ing centers (average in both of the 
present groups: 3.5 x normal), each 
of which adds a temporary deficit of 
approximately .003 mm- of bone to the 
envelope on which it lies. This repre-
sents a phase lag poo/." Because no 
correction was made for it, this too 
caused the computed values of Mr to 
be higher than their true ones. 
In other words, these data define 
an upper bound of Mr; the true values 
lie somewhere below. For these reasons 
(as well as others),-^ the depressed Mr 
in the dialysis group should not arise 
from sampling effects or from measur-
ing errors. 
Clearly we need independent con-
firmation of these results, particularly 
in more cases of primary hyperpara-
thyroidism. Clearly too the temptation 
to ascribe these findings to the effect 
of parathyroid hormone alone must be 
resisted, for many other existing factors 
in each group could have caused them. 
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